A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma
BP42233
Phase 1 other active
Quick answer
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma for Relapsed or Refractory Multiple Myeloma is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- other
- Status
- active